KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Sales (2016 - 2025)

Historic Return on Sales for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 0.26%.

  • Acadia Pharmaceuticals' Return on Sales rose 1300.0% to 0.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25%, marking a year-over-year increase of 1100.0%. This contributed to the annual value of 0.24% for FY2024, which is 3200.0% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Return on Sales stood at 0.26%, which was up 1300.0% from 0.1% recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Return on Sales high stood at 0.55% for Q4 2024, and its period low was 0.98% during Q1 2022.
  • Over the past 5 years, Acadia Pharmaceuticals' median Return on Sales value was 0.11% (recorded in 2021), while the average stood at 0.12%.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Return on Sales plummeted by -3600bps in 2022, and later soared by 6200bps in 2023.
  • Acadia Pharmaceuticals' Return on Sales (Quarter) stood at 0.33% in 2021, then rose by 7bps to 0.31% in 2022, then surged by 165bps to 0.2% in 2023, then soared by 180bps to 0.55% in 2024, then tumbled by -53bps to 0.26% in 2025.
  • Its Return on Sales stands at 0.26% for Q3 2025, versus 0.1% for Q2 2025 and 0.08% for Q1 2025.